NCT05271552Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

Study sponsor: BioXcel Therapeutics Inc

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-04-21Actual
Enrollment · participants151Actual
Source updated2026-08-11Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Absolute change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score. After: Measure: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview